Kymera Therapeutics News and Activities
Presence
Kymera Therapeutics develops medicines that target and degrade disease-causing proteins. Its services and drug candidates support patients, healthcare providers, and pharmaceutical partners in cancer, immune, and inflammatory diseases.
Kymera Therapeutics products and services overview:
- Protein degrader drugs
- Drug discovery
- Oncology therapies
- Immunology therapies
- Inflammation treatments
- Research partnerships
Revenue: ~$194 million
Employees: 270
Headquarters: Watertown, United States (USA)
Kymera Therapeutics is one of the...
Kymera Therapeutics is a company listed under the stock ticker KYMR (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Kymera Therapeutics
- Nello Mainolfi, Director, President and Chief Executive Officer
- Gorjan Hrustanovic, Director
- Pamela Esposito, Director
Popular executive movements at Kymera Therapeutics
- Bruce Booth who was Chairman of the Board, becomes Independent Director (posted on June 25 2026).
- Felix Baker who was Lead Independent Director, becomes Chairman of the Board (posted on June 25 2026).
- Penny Carlson has joined the company as Senior Vice President, Developmental Operations (posted on June 10 2026).
Click here to view some more movements at Kymera Therapeutics
Create your alert
to follow the executive moves at Kymera Therapeutics.
Biotechnology
Kymera Therapeutics has 2,417 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Zymeworks has announced the acquisition of Theravance Biopharma (posted on June 29 2026).
- Tissium has just announced a $68 Million fundraising (posted on June 29 2026).
- Oblenio Bio has just announced a $62 Million fundraising (posted on June 26 2026).
Popular contacts in Biotechnology
News
Press releases by Kymera Therapeutics
- Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma | Kymera Therap
- Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma | Kymera Therapeutics, Inc.
- Kymera Therapeutics to Participate in Upcoming September Investor Conferences | Kymera Therapeutics, Inc.
- Kymera Therapeutics to Report Second Quarter 2022 Results on August 9 | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan | Kymera Therapeutics, Inc.
- Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413 | Kymera Therapeutics, Inc.
- View more press releases Close
Social media about Kymera Therapeutics
- Kymera Therapeutics on Wikipedia, Google News & Yahoo Finance
- Kymera Therapeutics on LinkedIn, X (Twitter) & YouTube
